Table 3 Preoperative and postoperative tumor characteristics, and post-orthotopic liver transplantation recurrence.
DBD Group | uDCD Group | p value | |
|---|---|---|---|
(n = 103) | (n = 41) | ||
Pre-OLT tumor characteristics | |||
Tumor size at waitlisting (cm) | 2.7 ± 1.7 | 3 ± 1.2 | 0.402 |
Tumor number at waitlisting | 1(1–2) | 1 (1–2) | 0.402 |
AFP at waitlisting (ng/mL) | 5.1 (3.2–12.6) | 13.5 (5.3–54.5) | 0.603 |
Patients within Milan criteria | 86 (83.4%) | 39 (95.1%) | 0.200 |
Patients within UCSF criteria | 17 (16.6%) | 2 (4.9%) | 0.351 |
Time from HCC diagnosis to OLT (mo) | 19.1 ± 7.1 | 12.3 ± 7.1 | 0.038 |
Waitlist duration (mo) | 7.9 ± 5.4 | 5.3 ± 3 | 0.040 |
Pre-OLT therapy | 50 (48.5%) | 20 (48.8%) | 0.413 |
TACE | 44 (42.7%) | 16 (39.0%) | 0.841 |
Radiofrequency | 41 (39.8%) | 10 (24.4%) | 0.210 |
TACE + radiofrequency | 14 (9.7%) | 3 (7.3%) | 0.395 |
Post-OLT tumor characteristics | |||
Tumor size (cm) | 3.9 (2.1–6.6) | 4 (2.5–5.7) | 0.373 |
Tumor number | 2 (1–3) | 2 (2–3) | 0.436 |
Vascular invasion | 16 (15.5%) | 3 (7.3%) | 0.168 |
Microvascular invasion | 11(10.7%) | 3 (7.3%) | 0.256 |
Macrovascular invasion | 5 (4.8%) | 0 | 0.144 |
Perineural invasion | 0 | 1 (2.4%) | 0.291 |
Patients within Milan criteria | 61 (59.2%) | 27 (65.8%) | 0.503 |
Patients within UCSF | 23 (22.3%) | 7 (17.1%) | 0.440 |
Patients beyond UCSF | 19 (18.4%) | 7 (17.1%) | 0.528 |
Tumor recurrence after OLT | |||
Duration of follow-up after OLT (mo) | 52 ± 35 | 56 ± 44 | 0.550 |
Time from OLT to recurrence (mo) | 33 (3–48) | 12 (12–90) | 0.091 |
Recurrence rate | 8 (7.8%) | 3 (7.3%) | 0.597 |
Liver | 2 (1.9%) | 2 (4.9%) | 0.197 |
Bones | 3 (2.9%) | 1 (2.4%) | 0.197 |
Lungs | 3 (2.9%) | 0 (0%) | 0.197 |
Death from HCC recurrence | 4 (3.8%) | 1 (2.4%) | 0.545 |
